Illia Nechai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Illia Nechai has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
Borys Todurov
Department of Adult Cardiac Surgery, Heart Institute, Ministry of Healthcare of Ukraine, Kiev, Ukraine
5 shared publications- Igor Mokryk
Heart Institute of the Ministry of Health of Ukraine, Kyiv, Ukraine
5 shared publications - Borys M. Todurov
Shupyk National Healthcare University of Ukraine, Kyiv
4 shared publications Igor Mokryk
Department of Adult Cardiac Surgery, Heart Institute, Ministry of Healthcare of Ukraine, Kiev, Ukraine
3 shared publicationsIhor Stetsyuk
Department of Adult Cardiac Surgery, Heart Institute Ministry of Healthcare of Ukraine, Kyiv, Ukraine
3 shared publicationsVitaly Demyanchuk
Department of Adult Cardiac Surgery, Heart Institute, Ministry of Healthcare of Ukraine, Kiev, Ukraine
2 shared publications
Latest Publications
- Open Access
- 23 June 2026
- Published by Sumy State University in Eastern Ukrainian Medical Journal
- Vol. 14 (2) , 605-614
CONSERVATIVE VERSUS RADICAL TREATMENT OF ASCENDING AORTIC DILATION: COMPARATIVE ANALYSIS OF BASELINE CLINICAL DATA FOLLOWING WRAPPING, NO-TOUCH SURGICAL AORTIC VALVE REPLACEMENT, AND THE WHEAT PROCEDURE
Background: The optimal management of ascending aortic dilation in patients undergoing aortic valve replacement (AVR) remains debated. Although replacement of the ascending aorta is widely considered the standard, conservative strategies such as wrapping are still used in selected patients. Objective: This study aimed to analyze baseline characteristics and etiological patterns in patients treated with wrapping, supracoronary replacement (Wheat procedure), or isolated AVR without intervention on the ascending aorta. Methods: This retrospective, single-center analysis included 120 patients who underwent AVR in the presence of ascending aortic dilation (>40 mm) between 2016 and 2024. Patients with connective tissue disorders, prior aortic surgery, or acute aortic syndromes were excluded. After propensity score matching, 40 patients were assigned to each group: AVR with wrapping, Wheat procedure, and no-touch AVR. Demographic, clinical, and echocardiographic data were compared to identify factors associated with aortic dilation. Results: Patients in the No-touch group were significantly older (69.5 ± 5.2 years) compared with the Wheat (51.2 ± 13.7 years) and Wrapping (50.4 ± 13.3 years) groups (p < 0.001). Bicuspid valve morphology predominated in the Wheat (72.5%) and Wrapping (62.5%) groups, while tricuspid valves were most frequent in the No-touch group (80%; p < 0.001). Ascending aortic diameters were larger in the Wheat and Wrapping groups compared with No-touch (p < 0.001). The No-touch cohort showed more advanced ventricular remodeling, higher rates of left ventricular dilation, reduced ejection fraction, and increased pulmonary pressures. Neurological events and preoperative atrial fibrillation were also more common. Conclusion: Distinct etiological profiles exist among patients with ascending aortic dilation undergoing AVR. Wrapping and replacement were used mainly in younger patients with bicuspid valves and larger diameters, whereas the no-touch strategy was applied in older patients with tricuspid valves and ventricular dysfunction. These findings support individualized treatment based on valve phenotype, age, and etiology.
- 23 June 2026
- Published by Sumy State University in Eastern Ukrainian Medical Journal
- Vol. 14 (2) , 605-614
Open AccessCONSERVATIVE VERSUS RADICAL TREATMENT OF ASCENDING AORTIC DILATION: COMPARATIVE ANALYSIS OF BASELINE CLINICAL DATA FOLLOWING WRAPPING, NO-TOUCH SURGICAL AORTIC VALVE REPLACEMENT, AND THE WHEAT PROCEDURE
Background: The optimal management of ascending aortic dilation in patients undergoing aortic valve replacement (AVR) remains debated. Although replacement of the ascending aorta is widely considered the standard, conservative strategies such as wrapping are still used in selected patients. Objective: This study aimed to analyze baseline characteristics and etiological patterns in patients treated with wrapping, supracoronary replacement (Wheat procedure), or isolated AVR without intervention on the ascending aorta. Methods: This retrospective, single-center analysis included 120 patients who underwent AVR in the presence of ascending aortic dilation (>40 mm) between 2016 and 2024. Patients with connective tissue disorders, prior aortic surgery, or acute aortic syndromes were excluded. After propensity score matching, 40 patients were assigned to each group: AVR with wrapping, Wheat procedure, and no-touch AVR. Demographic, clinical, and echocardiographic data were compared to identify factors associated with aortic dilation. Results: Patients in the No-touch group were significantly older (69.5 ± 5.2 years) compared with the Wheat (51.2 ± 13.7 years) and Wrapping (50.4 ± 13.3 years) groups (p < 0.001). Bicuspid valve morphology predominated in the Wheat (72.5%) and Wrapping (62.5%) groups, while tricuspid valves were most frequent in the No-touch group (80%; p < 0.001). Ascending aortic diameters were larger in the Wheat and Wrapping groups compared with No-touch (p < 0.001). The No-touch cohort showed more advanced ventricular remodeling, higher rates of left ventricular dilation, reduced ejection fraction, and increased pulmonary pressures. Neurological events and preoperative atrial fibrillation were also more common. Conclusion: Distinct etiological profiles exist among patients with ascending aortic dilation undergoing AVR. Wrapping and replacement were used mainly in younger patients with bicuspid valves and larger diameters, whereas the no-touch strategy was applied in older patients with tricuspid valves and ventricular dysfunction. These findings support individualized treatment based on valve phenotype, age, and etiology.
- Open Access
- 31 March 2026
- Published by Chetverta Khvylia in Cardiac Surgery and Interventional Cardiology
- Vol. 15 (1) , 66-71
Хірургічне лікування гігантської аневризми правої коронарної артерії, ускладненої масивним тромбозом: клінічний випадок
Coronary artery aneurysm is a relatively rare pathology that may be complicated by thrombosis, embolization, or rupture. Giant aneurysms, particularly those containing an intraluminal thrombus, are associated with a high risk of acute coronary events and require timely determination of the optimal treatment strategy.The aim – to present a clinical case of successful surgical treatment of a giant right coronary artery (RCA) aneurysm complicated by massive intraluminal thrombosis and to justify the choice of aneurysm resection with simultaneous myocardial revascularization.We describe a 68-year-old patient with comorbidities (arterial hypertension, type 2 diabetes mellitus, and dyslipidemia) who presented with progressive chest pain for three days. The initial evaluation included laboratory tests, electrocardiography, and chest radiography. Coronary angiography with ventriculography was performed to assess the coronary circulation and revealed a giant saccular aneurysm of the proximal RCA measuring up to 50 mm, with a massive thrombus within the aneurysmal cavity. Surgery was performed via median sternotomy under cardiopulmonary bypass. The procedure included coronary artery bypass grafting (to the RCA and the left anterior descending artery), opening of the aneurysm, complete removal of thrombotic masses, resection of the aneurysmal sac, and subsequent closure.Results. The postoperative period was uneventful. Follow-up echocardiography demonstrated preserved left ventricular systolic function without signs of ischemia. The patient was discharged on postoperative day 8 in stable condition with recommendations for secondary prevention and a plan for follow-up monitoring. Control computed tomography performed one month later confirmed graft patency and the absence of aneurysm recurrence. During 12 months of follow-up, the patient reported no recurrent angina and experienced no cardiovascular events.Conclusions. Giant RCA aneurysms, particularly those complicated by massive thrombosis, carry a high risk of thromboembolic complications and require an active treatment strategy. Aneurysm resection combined with coronary artery bypass grafting is an effective and safe approach that eliminates a source of embolization and provides adequate myocardial revascularization.
- 31 March 2026
- Published by Chetverta Khvylia in Cardiac Surgery and Interventional Cardiology
- Vol. 15 (1) , 66-71
Open AccessХірургічне лікування гігантської аневризми правої коронарної артерії, ускладненої масивним тромбозом: клінічний випадок
Coronary artery aneurysm is a relatively rare pathology that may be complicated by thrombosis, embolization, or rupture. Giant aneurysms, particularly those containing an intraluminal thrombus, are associated with a high risk of acute coronary events and require timely determination of the optimal treatment strategy.The aim – to present a clinical case of successful surgical treatment of a giant right coronary artery (RCA) aneurysm complicated by massive intraluminal thrombosis and to justify the choice of aneurysm resection with simultaneous myocardial revascularization.We describe a 68-year-old patient with comorbidities (arterial hypertension, type 2 diabetes mellitus, and dyslipidemia) who presented with progressive chest pain for three days. The initial evaluation included laboratory tests, electrocardiography, and chest radiography. Coronary angiography with ventriculography was performed to assess the coronary circulation and revealed a giant saccular aneurysm of the proximal RCA measuring up to 50 mm, with a massive thrombus within the aneurysmal cavity. Surgery was performed via median sternotomy under cardiopulmonary bypass. The procedure included coronary artery bypass grafting (to the RCA and the left anterior descending artery), opening of the aneurysm, complete removal of thrombotic masses, resection of the aneurysmal sac, and subsequent closure.Results. The postoperative period was uneventful. Follow-up echocardiography demonstrated preserved left ventricular systolic function without signs of ischemia. The patient was discharged on postoperative day 8 in stable condition with recommendations for secondary prevention and a plan for follow-up monitoring. Control computed tomography performed one month later confirmed graft patency and the absence of aneurysm recurrence. During 12 months of follow-up, the patient reported no recurrent angina and experienced no cardiovascular events.Conclusions. Giant RCA aneurysms, particularly those complicated by massive thrombosis, carry a high risk of thromboembolic complications and require an active treatment strategy. Aneurysm resection combined with coronary artery bypass grafting is an effective and safe approach that eliminates a source of embolization and provides adequate myocardial revascularization.
- 13 January 2026
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- Vol. 74 (7) , 635-647
Neocuspidization versus bioprosthesis in surgical replacement of the aortic valve: a propensity-matched comparative analysis of immediate and mid-term outcomes
Objectives This study aims to compare the immediate and mid-term outcomes of Aortic Valve Neocuspidization (AVNeo) with surgical aortic valve replacement using a bioprosthesis (BioSAVR) to determine if neocuspidization can overcome limitations of current techniques. Methods From December 2016 to December 2023, 155 patients received AVNeo at the Heart Institute, while 301 underwent BioSAVR. Baseline characteristics were balanced using 1:1 propensity matching. Results 132 identical patient pairs were included in the analysis. Neocuspidization had longer ischemic times (98.67 ± 28.47 min vs. 66.76 ± 25.04 min, ρ < 0.001). Permanent pacemaker implantation (ρ = 0.072) and paravalvular leaks (ρ = 0.041) were more common in the BioSAVR group. Follow-up averaged 43.8 ± 27.30 months. Severe post-procedural aortic stenosis (PPAS) was more frequent after BioSAVR (3 (2.8%) vs. 1 (0.9%), ρ = 0.006), but AVNeo experienced more recurrent severe aortic regurgitation (AR) (3 (2.8%) vs. 0, ρ = 0.035). Reoperation rates were similar (AVNeo 3.1%, BioSAVR 1.5%, ρ = 0.680). Prosthetic valve endocarditis (PVE) was responsible for half (2 cases) of the AVNeo reoperations. Survival rate during follow-up was comparable: 92.8% (AVNeo) and 94.4% (BioSAVR), ρ = 0.672. Conclusions Immediate and mid-term AVNeo quality outcomes were comparable to those of BioSAVR. Transvalvular hemodynamics were better, and the incidence of PPAS was lower after AVNeo, supporting the recommendation of this procedure for patients at high risk of patient-prosthesis mismatch. During follow-up, AVNeo patients require close monitoring for recurrent AR and aggressive PVE prophylaxis. A multicenter long-term study is needed to confirm the stability of hemodynamic performance, the rate of Structural Valve Deterioration, and the incidence of PVE in AVNeo patients over the long term.
- 13 January 2026
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- Vol. 74 (7) , 635-647
Neocuspidization versus bioprosthesis in surgical replacement of the aortic valve: a propensity-matched comparative analysis of immediate and mid-term outcomes
Objectives This study aims to compare the immediate and mid-term outcomes of Aortic Valve Neocuspidization (AVNeo) with surgical aortic valve replacement using a bioprosthesis (BioSAVR) to determine if neocuspidization can overcome limitations of current techniques. Methods From December 2016 to December 2023, 155 patients received AVNeo at the Heart Institute, while 301 underwent BioSAVR. Baseline characteristics were balanced using 1:1 propensity matching. Results 132 identical patient pairs were included in the analysis. Neocuspidization had longer ischemic times (98.67 ± 28.47 min vs. 66.76 ± 25.04 min, ρ < 0.001). Permanent pacemaker implantation (ρ = 0.072) and paravalvular leaks (ρ = 0.041) were more common in the BioSAVR group. Follow-up averaged 43.8 ± 27.30 months. Severe post-procedural aortic stenosis (PPAS) was more frequent after BioSAVR (3 (2.8%) vs. 1 (0.9%), ρ = 0.006), but AVNeo experienced more recurrent severe aortic regurgitation (AR) (3 (2.8%) vs. 0, ρ = 0.035). Reoperation rates were similar (AVNeo 3.1%, BioSAVR 1.5%, ρ = 0.680). Prosthetic valve endocarditis (PVE) was responsible for half (2 cases) of the AVNeo reoperations. Survival rate during follow-up was comparable: 92.8% (AVNeo) and 94.4% (BioSAVR), ρ = 0.672. Conclusions Immediate and mid-term AVNeo quality outcomes were comparable to those of BioSAVR. Transvalvular hemodynamics were better, and the incidence of PPAS was lower after AVNeo, supporting the recommendation of this procedure for patients at high risk of patient-prosthesis mismatch. During follow-up, AVNeo patients require close monitoring for recurrent AR and aggressive PVE prophylaxis. A multicenter long-term study is needed to confirm the stability of hemodynamic performance, the rate of Structural Valve Deterioration, and the incidence of PVE in AVNeo patients over the long term.
- 3 May 2025
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- Vol. 73 (11) , 795-805
The utility of neocuspidization in the surgical management of congenital aortic valve pathology: mid-term results of single-center experience with AVNeo procedure in children
Background Aortic valve (AV) pathology in children presents a significant surgical challenge, with mid- and long-term outcomes of current techniques remaining controversial. This study evaluates our experience with aortic valve neocuspidization (AVNeo) in the pediatric population, analyzing immediate and mid-term results. Methods Ten children underwent AVNeo between June 2017 and August 2019. The clinical data were prospectively collected and retrospectively analyzed. The primary outcomes included failure to perform AVNeo, intraoperative conversion to the alternative technique, in-hospital mortality, and major adverse events. The secondary outcomes included aortic stenosis or regurgitation, valve-related events, reoperations, and mortality during follow-up. Results The median age was 9 (range: 2–17) years. AVNeo was feasible in all cases. Five children underwent previous cardiac interventions. Neocuspidization was feasible in all cases. No in-hospital mortality or significant postoperative complications occurred. Before discharge, average peak and mean pressure gradients were 13.5 mmHg and 6.5 mmHg, respectively. Aortic insufficiency was grade 0 or 1 in all cases. Seven patients required reoperation for valve dysfunction over a median follow-up of 73 months. The median time to reoperation was 62 months, with six patients undergoing mechanical valve replacement and one receiving a Ross procedure. Conclusion AVNeo offers excellent hemodynamic outcomes for children with AV pathology in the immediate postoperative period. However, the mid-term results revealed significant valve degeneration, necessitating reoperations in most cases. Unlike in adults, we do not consider AVNeo a definitive solution in children with AV disease. We see this technique as a valuable tool in the staged management of this congenital heart pathology.
- 3 May 2025
- Published by Springer Nature in General Thoracic and Cardiovascular Surgery
- Vol. 73 (11) , 795-805
The utility of neocuspidization in the surgical management of congenital aortic valve pathology: mid-term results of single-center experience with AVNeo procedure in children
Background Aortic valve (AV) pathology in children presents a significant surgical challenge, with mid- and long-term outcomes of current techniques remaining controversial. This study evaluates our experience with aortic valve neocuspidization (AVNeo) in the pediatric population, analyzing immediate and mid-term results. Methods Ten children underwent AVNeo between June 2017 and August 2019. The clinical data were prospectively collected and retrospectively analyzed. The primary outcomes included failure to perform AVNeo, intraoperative conversion to the alternative technique, in-hospital mortality, and major adverse events. The secondary outcomes included aortic stenosis or regurgitation, valve-related events, reoperations, and mortality during follow-up. Results The median age was 9 (range: 2–17) years. AVNeo was feasible in all cases. Five children underwent previous cardiac interventions. Neocuspidization was feasible in all cases. No in-hospital mortality or significant postoperative complications occurred. Before discharge, average peak and mean pressure gradients were 13.5 mmHg and 6.5 mmHg, respectively. Aortic insufficiency was grade 0 or 1 in all cases. Seven patients required reoperation for valve dysfunction over a median follow-up of 73 months. The median time to reoperation was 62 months, with six patients undergoing mechanical valve replacement and one receiving a Ross procedure. Conclusion AVNeo offers excellent hemodynamic outcomes for children with AV pathology in the immediate postoperative period. However, the mid-term results revealed significant valve degeneration, necessitating reoperations in most cases. Unlike in adults, we do not consider AVNeo a definitive solution in children with AV disease. We see this technique as a valuable tool in the staged management of this congenital heart pathology.
- Open Access
- 25 January 2025
- Published by National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications) in Science and innovation
- Vol. 21 (1) , 104-111
Glutaraldehyde-Treated Autologous Pericardium in Aortic Valve Reconstruction: an Optimal Material for Innovation Techniques. Review of the Literature
Introduction. Reconstructive operations on the aortic valve (AV) offer several advantages over standard AV replacement with mechanical or biological prostheses. This approach has allowed patients to avoid the adverse effects of long-term antithrombotic therapy. Furthermore, it has preserved the natural mobility of the left ventricular outflow tract, resulting in improved hemodynamics across the valve. Materials for reconstruction are often readily available, making the method economically attractive.Problem Statement. Autologous pericardium is the most commonly used material in AV reconstruction. Glutaraldehyde treatment of autologous pericardium (GTAP) has provided tissue with enhanced mechanical properties and reduced thrombogenicity. However, the long-term degeneration of biological tissues used in AV surgery has remained a concern despite glutaraldehyde treatment.Purpose. This study has aimed to evaluate the current status and future prospects for the use of GTAP in reconstructive AV surgery.Materials and Methods. A literature search has been conducted using PubMed, Web of Science, and the Google search engine. All studies on GA-fixed pericardial tissue published up to March 2023 have been identified. A total of 165 articles have been initially retrieved, of which 20 relevant studies are included in this review. Results. GTAP has demonstrated excellent elasticity and surgical handling characteristics. It has enabled complex AV reconstructions with sustained immediate transvalvular hemodynamics. Degeneration and calcification rates of GTAP have been comparable to those observed in existing biological prostheses.Conclusions. GTAP off ers signifi cant potential for advancing techniques in aortic valve pathology correction. It is cost-effective, readily available, and facilitates effective valve reconstruction. However, aggressive prophylaxis for infective endocarditis remains mandatory in the postoperative period. Further multicenter studies with larger cohorts are essential to better delineate the long-term prospects and limitations of GTAP in AV surgery.
- 25 January 2025
- Published by National Academy of Sciences of Ukraine (Co. LTD Ukrinformnauka) (Publications) in Science and innovation
- Vol. 21 (1) , 104-111
Open AccessGlutaraldehyde-Treated Autologous Pericardium in Aortic Valve Reconstruction: an Optimal Material for Innovation Techniques. Review of the Literature
Introduction. Reconstructive operations on the aortic valve (AV) offer several advantages over standard AV replacement with mechanical or biological prostheses. This approach has allowed patients to avoid the adverse effects of long-term antithrombotic therapy. Furthermore, it has preserved the natural mobility of the left ventricular outflow tract, resulting in improved hemodynamics across the valve. Materials for reconstruction are often readily available, making the method economically attractive.Problem Statement. Autologous pericardium is the most commonly used material in AV reconstruction. Glutaraldehyde treatment of autologous pericardium (GTAP) has provided tissue with enhanced mechanical properties and reduced thrombogenicity. However, the long-term degeneration of biological tissues used in AV surgery has remained a concern despite glutaraldehyde treatment.Purpose. This study has aimed to evaluate the current status and future prospects for the use of GTAP in reconstructive AV surgery.Materials and Methods. A literature search has been conducted using PubMed, Web of Science, and the Google search engine. All studies on GA-fixed pericardial tissue published up to March 2023 have been identified. A total of 165 articles have been initially retrieved, of which 20 relevant studies are included in this review. Results. GTAP has demonstrated excellent elasticity and surgical handling characteristics. It has enabled complex AV reconstructions with sustained immediate transvalvular hemodynamics. Degeneration and calcification rates of GTAP have been comparable to those observed in existing biological prostheses.Conclusions. GTAP off ers signifi cant potential for advancing techniques in aortic valve pathology correction. It is cost-effective, readily available, and facilitates effective valve reconstruction. However, aggressive prophylaxis for infective endocarditis remains mandatory in the postoperative period. Further multicenter studies with larger cohorts are essential to better delineate the long-term prospects and limitations of GTAP in AV surgery.
- Open Access
- 24 September 2024
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 25 (2) , 338-345
Natural biomaterials in the management of the aortic valve pathology. Biomedical and clinical aspects: A review
Heart valve diseases are a prevalent cardiovascular pathology worldwide, affecting nearly 2.5% of the population. Degenerative aortic stenosis is the most common form of heart valve disease. The treatment options include surgical or transcatheter procedures. There are two main categories of valve prostheses available: mechanical heart valves constructed from synthetic materials and bioprosthetic heart valves made from natural biomaterials. The choice of valve type depends on various factors, including the underlying medical condition, suitability for anticoagulation, valve durability, and the patient’s age and preferences. Mechanical heart valves have the advantage of long-term durability. However, patients receiving mechanical implants are subjected to lifelong anticoagulation therapy with an increased risk of thromboembolism and bleeding. Natural biomaterials do not require long-term anticoagulation. However, they experience degenerative changes leading to structural valve deterioration that may require reoperation. The purpose of this article is to review the role of natural biological materials used for aortic valve replacement or repair, assess their biomedical and clinical advantages and limitations, and analyze the direction and perspectives of future development.
- 24 September 2024
- Published by Association of Basic Medical Sciences of FBIH in Biomolecules and Biomedicine
- Vol. 25 (2) , 338-345
Open AccessNatural biomaterials in the management of the aortic valve pathology. Biomedical and clinical aspects: A review
Heart valve diseases are a prevalent cardiovascular pathology worldwide, affecting nearly 2.5% of the population. Degenerative aortic stenosis is the most common form of heart valve disease. The treatment options include surgical or transcatheter procedures. There are two main categories of valve prostheses available: mechanical heart valves constructed from synthetic materials and bioprosthetic heart valves made from natural biomaterials. The choice of valve type depends on various factors, including the underlying medical condition, suitability for anticoagulation, valve durability, and the patient’s age and preferences. Mechanical heart valves have the advantage of long-term durability. However, patients receiving mechanical implants are subjected to lifelong anticoagulation therapy with an increased risk of thromboembolism and bleeding. Natural biomaterials do not require long-term anticoagulation. However, they experience degenerative changes leading to structural valve deterioration that may require reoperation. The purpose of this article is to review the role of natural biological materials used for aortic valve replacement or repair, assess their biomedical and clinical advantages and limitations, and analyze the direction and perspectives of future development.
- Open Access
- 1 January 2024
- Published by Editorial Committee of Annals of Thoracic and Cardiovascular Surgery in Annals of Thoracic and Cardiovascular Surgery
- Vol. 30 (1)
Complete Aortic Valve Reconstruction with Autologous Pericardium: Analysis of Mid-Term Results of Single-Center Experience with AVNeo Procedure
Purpose: Aortic valve neocuspidization (AVNeo) is a relatively recent advancement in surgical AV replacement. Data on its performance beyond the short term are limited. We assessed the mid-term outcomes in patients undergoing AVNeo, focusing on feasibility, perioperative details, and its role in AV pathology treatment.Methods: Sixty-five consecutive patients underwent AVNeo between December 2016 and February 2018. Clinical data were prospectively collected and retrospectively analyzed. Tricuspid reconstruction with autologous pericardium was performed in all cases. Echocardiographic follow-up was conducted post-discharge, at 6 and 12 months, and annually thereafter.Results: The mean age was 62.6 ± 18.7 years. AVNeo was feasible in all cases. Concomitant procedures were performed in 43 (66.2%) patients. Mean bypass and cross-clamp times were 119.2 ± 30.3 and 87.1 ± 22.9 minutes, respectively. Postoperative transvalvular hemodynamics was excellent. There was one (1.5%) in-hospital death. Follow-up (mean 66.72 ± 12.77 months) was complete in 58 patients (89.2%). There were no detected valve-related or thromboembolic events. Transvalvular hemodynamic parameters were stable during the observation period: peak pressure gradient at discharge and follow-up was 15.3 ± 4.6 mmHg and 15.01 ± 6.3 mmHg, respectively (ρ = 0.346).Conclusions: AVNeo demonstrated the feasibility and favorable mid-term outcomes. Studies with longer-term observation are warranted to evaluate its durability.
- 1 January 2024
- Published by Editorial Committee of Annals of Thoracic and Cardiovascular Surgery in Annals of Thoracic and Cardiovascular Surgery
- Vol. 30 (1)
Open AccessComplete Aortic Valve Reconstruction with Autologous Pericardium: Analysis of Mid-Term Results of Single-Center Experience with AVNeo Procedure
Purpose: Aortic valve neocuspidization (AVNeo) is a relatively recent advancement in surgical AV replacement. Data on its performance beyond the short term are limited. We assessed the mid-term outcomes in patients undergoing AVNeo, focusing on feasibility, perioperative details, and its role in AV pathology treatment.Methods: Sixty-five consecutive patients underwent AVNeo between December 2016 and February 2018. Clinical data were prospectively collected and retrospectively analyzed. Tricuspid reconstruction with autologous pericardium was performed in all cases. Echocardiographic follow-up was conducted post-discharge, at 6 and 12 months, and annually thereafter.Results: The mean age was 62.6 ± 18.7 years. AVNeo was feasible in all cases. Concomitant procedures were performed in 43 (66.2%) patients. Mean bypass and cross-clamp times were 119.2 ± 30.3 and 87.1 ± 22.9 minutes, respectively. Postoperative transvalvular hemodynamics was excellent. There was one (1.5%) in-hospital death. Follow-up (mean 66.72 ± 12.77 months) was complete in 58 patients (89.2%). There were no detected valve-related or thromboembolic events. Transvalvular hemodynamic parameters were stable during the observation period: peak pressure gradient at discharge and follow-up was 15.3 ± 4.6 mmHg and 15.01 ± 6.3 mmHg, respectively (ρ = 0.346).Conclusions: AVNeo demonstrated the feasibility and favorable mid-term outcomes. Studies with longer-term observation are warranted to evaluate its durability.
- Open Access
- 1 January 2023
- Published by Termedia Sp. z.o.o. in Polish Journal of Cardio-Thoracic Surgery
- Vol. 20 (4) , 263-265
Mixed rheumatic tricuspid valve disease: details of preoperative evaluation and surgical management
- 1 January 2023
- Published by Termedia Sp. z.o.o. in Polish Journal of Cardio-Thoracic Surgery
- Vol. 20 (4) , 263-265
Open AccessMixed rheumatic tricuspid valve disease: details of preoperative evaluation and surgical management